Clinical Trials · NCT05051566
A Multiple Dose Study of LY3502970 in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 26
- Start date
- Sep 2021
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation